蛋白酶3特异性抗中性粒细胞胞质抗体相关性血管炎
本文为综述,阐述蛋白酶3(PR3)特异性抗中性粒细胞胞质抗体(ANCA)相关性血管炎与肉芽肿性多血管炎(GPA)的病理联系、组织病理与临床特征、发病机制及当前与未来靶向治疗;利妥昔单抗成功用于缓解诱导与维持治疗,复发与标准治疗毒性仍导致死亡和损伤相关疾病。
要点
- PR3-ANCA相关性血管炎是ANCA相关性血管炎两大变异型之一,与GPA存在致病性关联。
- GPA以坏死性肉芽肿性炎症为特征,优先累及呼吸道,其小血管炎特征与显微镜下多血管炎共有。
- B细胞在PR3-ANCA相关性血管炎发病机制中居中心地位,利妥昔单抗可成功靶向B细胞用于缓解诱导与维持治疗。
核心结论
- PR3-ANCA相关性血管炎与GPA存在致病性关联,GPA的坏死性肉芽肿性炎症可通过激活中性粒细胞和单核细胞导致PR3-ANCA及小血管炎。
- B细胞是PR3-ANCA相关性血管炎发病机制的核心,利妥昔单抗用于缓解诱导和维持治疗可成功靶向B细胞。
- PR3-ANCA相关性血管炎的复发及当前标准治疗相关毒性对残余死亡和损伤相关疾病负担有实质贡献,需要更有效且毒性更低的治疗。
研究设计与样本
- 本文为系列综述,描述PR3-ANCA相关性血管炎相互关联的组织病理与临床特征、病理生理学以及当前和未来的靶向治疗。
主要发现
- GPA以坏死性肉芽肿性炎症为特征,优先累及呼吸道,其小血管炎特征与显微镜下多血管炎共有。
- GPA的坏死性肉芽肿性炎症可通过激活中性粒细胞和单核细胞导致PR3-ANCA和小血管炎。
- B细胞在PR3-ANCA相关性血管炎发病机制中居中心地位,利妥昔单抗用于缓解诱导和维持治疗可成功靶向B细胞。
- PR3-ANCA相关性血管炎的复发及当前标准治疗相关毒性对残余死亡和损伤相关疾病负担有实质贡献。
- 细胞及新型抗原特异性免疫疗法的进展有望应用于自身免疫病,包括PR3-ANCA相关性血管炎。
临床怎么用
- 利妥昔单抗用于缓解诱导和维持治疗可成功靶向B细胞。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Proteinase 3 (PR3)-specific antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is one of two major ANCA-associated vasculitis variants and is pathogenically linked to granulomatosis with polyangiitis (GPA). GPA is characterised by necrotising granulomatous inflammation that preferentially affects the respiratory tract. The small vessel vasculitis features of GPA are shared with microscopic polyangiitis. Necrotising granulomatous inflammation of GPA can lead to PR3-ANCA and small vessel vasculitis via activation of neutrophils and monocytes. B cells are central to the pathogenesis of PR3-ANCA-associated vasculitis. They are targeted successfully by remission induction and maintenance therapy with rituximab. Relapses of PR3-ANCA-associated vasculitis and toxicities associated with current standard therapy contribute substantially to remaining mortality and damage-associated morbidity. More effective and less toxic treatments are sought to address this unmet need. Advances with cellular and novel antigen-specific immunotherapies hold promise for application in autoimmune disease, including PR3-ANCA-associated vasculitis. This Series paper describes the inter-related histopathological and clinical features, pathophysiology, as well as current and future targeted treatments for PR3-ANCA-associated vasculitis.
引用
- Falde SD, Fussner LA, Tazelaar HD, et al. Proteinase 3-specific antineutrophil cytoplasmic antibody-associated vasculitis. Lancet Rheumatol. 2024. PMID: 38574742. doi:10.1016/S2665-9913(24)00035-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。